Medicare can pay for obesity drugs like Wegovy in certain heart patients
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles
- (ECNS) -- China's first self-developed icebreaker Xuelong 2, or Snow Dragon 2, is expected to pay a2024-05-01
China retrieves subglacial bedrock sample from East Antarctic
(ECNS) -- Chinese scientists from Jilin University successfully extracted samples of ice core and su2024-05-01Double blow for UK's Johnson as two Cabinet ministers quit
[PHOTO/AGENCIES]The United Kingdom's finance minister, Chancellor of the Exchequer Rishi Sunak, and2024-05-01Technological innovation progress comes with rise of China's Silicon Valley
(Xinhua) 09:28, May 27, 2023* From May 25 to 30, the ongoing 2023 Zhongguancun Forum commands the wo2024-05-01Multinational enterprises confident of China's economic growth target
(ECNS) -- Against the backdrop of sluggish global economic growth, China's anticipation of a growth2024-05-01NATO's bigger remit brings rising dangers
NATO Secretary-General Jens Stoltenberg speaks during a press conference at a NATO summit in Madrid,2024-05-01
atest comment